
XTNT Stock Forecast & Price Target
XTNT Analyst Ratings
Bulls say
Xtant Medical Holdings is poised for success in the medical technology industry as it focuses on its core business of orthobiologics and spinal implants. With the recent Dilon Technologies agreement, a strong capital position, and a discounted valuation compared to its peers, Xtant Medical is positioned for revenue growth and profitability. The company's product pipeline, including the recent launch of Trivium Shaped, showcases its commitment to innovation and meeting the needs of orthopedic and neurological surgeons. Risks include competition, legacy performance, and the need for additional capital, but the company's recent changes and clean-up process demonstrate its ability to adapt and improve. Overall, Xtant Medical has a positive outlook for future growth and potential to provide value for investors.
Bears say
Xtant Medical Holdings is facing a potential growth plateau in the near-term due to their reliance on a single distributor for a significant portion of their revenue. Ongoing inventory dynamics in the wound care market may also hinder their ability to drive sales in this segment. Additionally, their limited financial resources may impede their ability to effectively compete with larger, more established competitors in the market.
This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.
XTNT Analyst Forecast & Price Prediction
Start investing in XTNT
Order type
Buy in
Order amount
Est. shares
0 shares